Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Genmab A/S - American Depositary Shares (NQ:GMAB)

28.27 -1.03 (-3.52%)
Streaming Delayed Price Updated: 2:22 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 857,970
Open 28.98
Bid (Size) 28.26 (200)
Ask (Size) 28.28 (400)
Prev. Close 29.30
Today's Range 28.15 - 29.08
52wk Range 18.89 - 35.43
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
From Genmab A/S
Via Business Wire
News headline image
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer. 
Via The Motley Fool

Performance

YTD
-11.2%
-11.2%
1 Month
+6.4%
+6.4%
3 Month
-20.0%
-20.0%
6 Month
-13.6%
-13.6%
1 Year
+44.9%
+44.9%

More News

Read More
News headline image
AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
Via MarketMinute
Topics ETFs Economy Intellectual Property
Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case ↗
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP Investment ↗
Via Chartmill
Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth ↗
Via Chartmill
GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment ↗
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation ↗
Via Chartmill
GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals ↗
Via Chartmill
News headline image
My Top 4 Stocks to Buy in Early 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Genmab Reports Mixed Results From Late-Stage Trial Of Lymphoma Drug ↗
Via Stocktwits
News headline image
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) Passes Peter Lynch's GARP Investment Screen ↗
Via Chartmill
News headline image
Why Are Investors Paying Attention To Genmab Stock? ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
From Genmab A/S
Via Business Wire
News headline image
Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗
Via Stocktwits
Topics Supply Chain
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Genmab Portfolio Prioritization Update
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
News headline image
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
News headline image
Genmab (GMAB) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer ↗
Via Benzinga
News headline image
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?
Yes, Genmab A/S - American Depositary Shares is publicly traded.
What exchange does Genmab A/S - American Depositary Shares trade on?
Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Genmab A/S - American Depositary Shares?
The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market
What is the current price of Genmab A/S - American Depositary Shares?
The current price of Genmab A/S - American Depositary Shares is 28.27
When was Genmab A/S - American Depositary Shares last traded?
The last trade of Genmab A/S - American Depositary Shares was at 04/16/26 02:22 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.